Corporate
News release
TopTerumo Aortic has announced the completion of enrolment of the RelayPro pivotal study in the United States. RelayPro is a low profile, next generation thoracic stent graft device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels.
RelayPro, having obtained CE Mark in 2018, utilises the same stent design, material and dual sheath technology already proven in Terumo Aortic's RelayPlus device, with the additional benefit of a 3 to 4 Fr reduction in outer profile.
The RelayPro aneurysm study is a prospective, multi-centre, non-blinded, non-randomised study of the RelayPro thoracic stent graft in patients with thoracic aortic aneurysms and penetrating atherosclerotic ulcers. The primary endpoint for safety is a composite of major adverse events; the primary endpoint for effectiveness is a composite of technical and clinical success.
One-hundred and ten patients have been enrolled in the study across sites in both the United States and Japan.
Dr Wilson Szeto (Cardiothoracic surgeon, University Medical Centre of Pennsylvania) Co-Principal Investigator, commented, "RelayPro's ability to land accurately combined with its low profile will allow me to successfully treat complex anatomy with precision."
This trial marks the first time both Bare Stent and Non-Bare Stent (NBS) configurations of RelayPro have been used in the United States. Dr Venkatesh Ramaiah (Vascular surgeon, HonorHealth Medical Group, Arizona) Co-Principal Investigator, stated, "One of the key benefits of RelayPro is being able to choose from a range of proximal configurations allowing me to tailor my device selection to meet the individual needs of each patient."
The completion of enrolment is an important milestone for Terumo Aortic as the company progresses towards the approval of RelayPro in the United States and Japan.
About Terumo Aortic
At Terumo Aortic, we understand that no two aortas are alike; our company's vision is to transform the treatment of aortic disease worldwide. We are 100% focused on the aorta, from the arch to the iliacs. With our comprehensive portfolio of surgical, endovascular and hybrid technologies and services, we help clinicians address their patients' unique challenges -- so no patient is left behind.
Notes to Editors
- Terumo Corporation of Japan, a global medical device company founded in 1921 currently has over 25,000 employees worldwide
- Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc in 2017
- Terumo Aortic has over 1,250 employees including 815 located in Glasgow, Scotland; 330 in Sunrise, Florida and the remaining within direct European markets.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.